Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Rating) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Friday. A number of other equities analysts have also recently issued reports on MDGL. Canaccord Genuity Group raised their target price on Madrigal Pharmaceuticals from $296.00 to $336.00 […]
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Rating) has been assigned an average rating of “Moderate Buy” from the fourteen ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company. […]
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Rating) have earned an average recommendation of “Buy” from the ten research firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating on the company. The average 12 month price […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Thursday, Zacks.com reports. According to Zacks, “Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered […]